ATYR aTyr Pharma, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ATYR matters now
aTyr Pharma, Inc. (ATYR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.58 with -9.55% on the session and $57.0M in market capitalization; recent performance reads 1-month -6.73% and YTD -42.47%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.8M, and EPS of $-0.11. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -134.2%.
The latest indexable market news headline is "aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $1.25; recent insider activity includes SCHIMMEL PAUL filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.76
P/S
232.48
EV/EBITDA
-0.67
DCF Value
$-0.04
FCF Yield
-134.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11754.7%
Operating Margin
-38573.7%
Net Margin
-36857.4%
ROE
-99.9%
ROA
-87.9%
ROIC
-105.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.8M | $-0.11 |
| Q4 2025 | $0.00 | $-14.0M | $-0.14 |
| FY 2025 | $190.0K | $-74.1M | $-0.80 |
| Q3 2025 | $190.0K | $-25.7M | $-0.26 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.13
Target (Median)
$1.25
Target Range
$1.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.54
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.